PD-1/PD-L1抑制剂治疗膀胱癌的研究进展  

Advances in Treatment of Bladder Cancer with Programmed Cell Death-1/Programmed Cell Death Ligand-1 Inhibitors

作　　者：杨晓岚 田俊强[1] YANG Xiaolan;TIAN Junqiang.(Department of Urology,the Second Affiliated Hospital of Lanzhou University/Urinary System Diseases Key Laboratory of Gansu Province/Gansu Clinical MedicalCenter of Urinary System Diseases,Lanzhou 730000,China)

机构地区：[1]兰州大学第二医院泌尿外科甘肃省泌尿系统疾病重点实验室甘肃省泌尿系统疾病临床医学中心

出　　处：《医学综述》2019年第17期3411-3416,3421,共7页Medical Recapitulate

基　　金：兰州市城关区科技计划项目(2017KJGG0052);兰州大学第二医院第二批博士科研基金(ynbskyjj2015-2-7)

摘　　要：膀胱癌是泌尿系统常见的恶性肿瘤之一,发病机制复杂、易复发,给予积极治疗预后仍较差。随着恶性肿瘤治疗研究的不断深入,免疫治疗成为治疗模式的中心,程序性细胞死亡受体-1(PD-1)/程序性细胞死亡配体-1(PD-L1)抑制剂在治疗膀胱癌等多种肿瘤中显示出持久的抗肿瘤效应及可耐受的安全性,患者的总生存获益明显提高。目前,Nivolumab、Pembrolizumab、Atezolizumab、Durvalumab、Avelumab等作为免疫抑制剂已被批准用于临床膀胱癌的治疗,针对PD-1/PD-L1抑制剂的临床试验正在大规模开展,为膀胱癌的治疗带来了希望。Bladder cancer is one of the common malignant tumors in the urinary system,with complex pathogenesis and easy recurrence.The prognosis is still poor after active treatment.With the development of cancer treatment,immunotherapy has become the center of treatment model.Programmed cell death receptor-1/programmed cell death ligand-1(PD-1/PD-L1)inhibitors have shown long-lasting anti-tumor effects and tolerable safety in the treatment of bladder cancer and other tumors,which can significantly improve the overall survival benefit of the patients.At present,nivolumab,pembrolizumab,atezolizumab,durvalumab and avelumab have been approved as immunosuppressants for the treatment of bladder cancer.Clinical trials of PD-1/PD-L1 inhibitors are being carried out on a large scale,which brings hope to the treatment of bladder cancer.

关 键 词：膀胱癌 程序性死亡受体-1/程序性死亡配体-1抑制剂 免疫治疗 免疫抑制剂 

分 类 号：R737.1[医药卫生—肿瘤] R730.3[医药卫生—临床医学]